[Clinical trials of recombinant gamma-interferon. Circulating interferon and the 2,5-oligoadenylate synthetase activity after intramuscular and inhalation administrations].
It was shown that human recombinant gamma IFN given to volunteers intramuscularly (90 x 10(3) IU) and by inhalation (120 x 10(3) IU) induced 5-10-fold increase circulating IFN (up to 40-60 IU/ml); the activities of 2,5-oligoadenylate synthetase increased 1.5-2 fold and protein kinase of lymphocytes--3-5-fold. The repeated doses of gamma IFN at 12-15-hour intervals maintained a relatively stable IFN status, the inhalatory route of application being more effective. Convalescents after influenza different from healthy donors by a higher level of serum interferon and activity of 2.5-oligoadenylate synthetase but the activity of protein kinase was lowered in lymphocytes and plasma. The side effects induced by IFN administration were more marked only after intramuscular injections of 90 10 IU and were absent after inhalation of IFN (120,000 IU).
Sokolova
T M
TM
Lopatina
O A
OA
Nosik
N N
NN
Cheshik
S G
SG
D015088:2',5'-Oligoadenylate Synthetase / Q000097:blood / Q000187:drug effects*; D000280:Administration, Inhalation; D006801:Humans; D007273:Injections, Intramuscular; D007371:Interferon-gamma / Q000008:administration & dosage* / Q000009:adverse effects; D007372:Interferons / Q000097:blood / Q000187:drug effects*; D008297:Male; D011494:Protein Kinases / Q000097:blood / Q000187:drug effects*; D011994:Recombinant Proteins; D013997:Time Factors
D011994:Recombinant Proteins; D007371:Interferon-gamma; D007372:Interferons; D011494:Protein Kinases; D015088:2',5'-Oligoadenylate Synthetase